Dr Reddys Laboratories (RDY) Operating Leases (2021 - 2026)

Dr Reddys Laboratories has reported Operating Leases for 6 years, with the latest figure at $27.4 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 209.69% year-over-year to $27.4 million in Q1 2026; TTM through Mar 2026 was $27.4 million, a 209.69% increase from a year earlier, with the FY2026 full-year figure at $28.3 million, up 213.06% from the prior year.
• Operating Leases was $27.4 million for Q1 2026 at Dr Reddys Laboratories, up from $8.8 million in the prior quarter.
• The five-year high for Operating Leases was $27.4 million in Q1 2026, with the low at $2.6 million in Q1 2022.
• Average Operating Leases over 5 years is $8.9 million, with a median of $5.6 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Operating Leases plunged 92.36% in 2022, then jumped 209.69% in 2026.
• Over 5 years, Operating Leases stood at $2.6 million in 2022, then jumped by 103.16% to $5.3 million in 2023, then rose by 11.98% to $6.0 million in 2024, then jumped by 48.21% to $8.8 million in 2025, then surged by 209.69% to $27.4 million in 2026.
• The last three Operating Leases figures came in at $27.4 million (Q1 2026), $8.8 million (Q1 2025), and $6.0 million (Q1 2024), per Business Quant data.